SALIM VIRANI to Secondary Prevention
This is a "connection" page, showing publications SALIM VIRANI has written about Secondary Prevention.
Connection Strength
5.796
-
Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Prog Cardiovasc Dis. 2021 Sep-Oct; 68:2-6.
Score: 0.682
-
Secondary prevention of cardiovascular diseases in India: Findings from registries and large cohorts. Indian Heart J. 2020 Sep - Oct; 72(5):337-344.
Score: 0.640
-
Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia. Circulation. 2020 04 07; 141(14):1121-1123.
Score: 0.622
-
The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Curr Atheroscler Rep. 2019 04 02; 21(6):20.
Score: 0.580
-
Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
Score: 0.570
-
Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Tex Heart Inst J. 2013; 40(3):288-9.
Score: 0.376
-
Guideline-Concordant Statin Therapy Use?in Secondary Prevention: Should the Medical Community Wait for Divine Intervention? J Am Coll Cardiol. 2022 05 10; 79(18):1814-1817.
Score: 0.180
-
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
Score: 0.172
-
Epidemiology and risk factors for stroke in young individuals: implications for prevention. Curr Opin Cardiol. 2021 09 01; 36(5):565-571.
Score: 0.171
-
Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
Score: 0.169
-
Contemporary outcomes studies to identify and mitigate the risk in patients with premature cardiovascular disease. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):559-570.
Score: 0.165
-
Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
Score: 0.164
-
Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005455.
Score: 0.151
-
Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Prog Cardiovasc Dis. 2019 Sep - Oct; 62(5):406-413.
Score: 0.151
-
Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. J Am Heart Assoc. 2019 10; 8(19):e013229.
Score: 0.150
-
Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Curr Atheroscler Rep. 2019 06 22; 21(9):32.
Score: 0.147
-
Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. J Am Heart Assoc. 2018 09 18; 7(18):e009251.
Score: 0.140
-
Statin Use and Adverse Effects Among Adults >75?Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018 05 08; 7(10).
Score: 0.136
-
Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 01 01; 2(1):47-54.
Score: 0.124
-
Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020. Eur J Prev Cardiol. 2022 10 20; 29(14):1830-1838.
Score: 0.046
-
Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007237.
Score: 0.043
-
A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. Glob Heart. 2019 09; 14(3):215-240.
Score: 0.037
-
Sex Differences in the Use of Statins in Community Practice. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005562.
Score: 0.037
-
Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J. 2019 08; 214:113-124.
Score: 0.037
-
Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiol. 2019 05 01; 4(5):473-477.
Score: 0.036
-
Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. J Am Heart Assoc. 2019 04 02; 8(7):e011765.
Score: 0.036
-
Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA Cardiol. 2018 08 01; 3(8):739-748.
Score: 0.035